BioTuesdays

Tag - Roanna Ruiz

New-Amsterdam-Logo
Markets

SVB starts NewAmsterdam Pharma at OP; PT $19

SVB Securities initiated coverage of NewAmsterdam Pharma (NASDAQ:NAMS) with an “outperform” rating and $19 price target. The stock closed at $11.31 on Dec. 19. “We believe there is a place for NewAmsterdam’s...

December 20, 2022
scPharmaceuticals Logo
Markets

SVB ups scPharmaceuticals on FDA approval of Furoscix

SVB Securities upgraded scPharmaceuticals (NASDAQ:SCPH) to “outperform” from “market perform” and raised its price target to $11 from $6 after FDA approval of Furoscix for treatment of congestion in chronic heart...

October 11, 2022
Amarin
Markets

Analysts downgrade Amarin; PTs cut to $3

Analysts for H.C. Wainwright and SVB Securities downgraded Amarin (NASDAQ:AMRN) to “neutral” from “ buy” and to “market perform” from “outperform,” respectively. Both analysts cut their prices targets to $3 from $10...

May 5, 2022
Aligos-Therapeutics
Markets

SVB cuts Aligos to market perform; PT to $3 from $7

SVB Securities downgraded Aligos Therapeutics (NASDAQ:ALGS) to “market perform” from “outperform” and slashed its price target to $3, which is close to cash, from $7, citing a slow catalyst path ahead with a legal...

May 5, 2022
Atea Pharmaceuticals
Markets

SVB Leerink cuts Atea Pharma PT to $20 from $60

SVB Leerink slashed its price target for Atea Pharmaceuticals (NASDAQ:AVIR) to $20 from $60 but maintained its “outperform” rating after the company’s Phase 2 MOONSONG trial in COVID-19 outpatients did not hit its...

October 20, 2021
ContraFect Logo
Markets

SVB Leerink starts ContraFect at OP; PT $14

SVB Leerink initiated coverage of ContraFect (NASDAQ:CFRX) with an “outperform” rating and sum-of-the-parts price target of $14. The stock closed at $3.90 on Sept. 8. Analyst Roanna Ruiz, Ph.D., writes that...

September 9, 2021
Aligos-Therapeutics
Markets

SVB Leerink starts Aligos Therapeutics at OP; PT $29

SVB Leerink initiated coverage of Aligos Therapeutics (NASDAQ:ALGS) with an “outperform” rating and $29 price target. The stock closed at $15.31 on Sept. 8. Analyst Roanna Ruiz, Ph.D., writes that Aligos is unique among...

September 9, 2021
scPharmaceuticals
Markets

SVB Leerink starts scPharmaceuticals at MP; PT $6

SVB Leerink launched coverage of scPharmaceuticals (NASDAQ:SCPH) with a “market perform” rating sum-of-the-parts PT of $6. The stock closed at $5.95 on Sept. 8. Analyst Roanna Ruiz, Ph.D., writes that, among other...

September 9, 2021